PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

DEC 2 1 2004 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTQ1

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/207,635 10/053530			
Filing Date	July 25, 2002			
First Named Inventor	LEDBETTER			
Art Unit	1642			
Examiner Name	HELMS, LARRY R.			
Attomey Docket Number	49076-000004.utl2			

			U. S. PATENT	DOCUMENTS		
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
10		Number-Kind Code ² (I known)	10.01.1000	MERCK PATENT GMBH (D		
Дw		^{US-} 5844093	12-01-1998			
		^{US-} 5736137	04-07-1998	RASTETTER W. et al		
		^{US-} 5776456	07-07-1998	RASTETTER W. et al	,	
		^{US-} 20030133930	07-17-2003	Goldenberg et al.		
		^{US-} 2003-0219433	02-14-2003	Hansen H.		
		US-USEN 09/590,284	08-09-2000	Goldenberg et al.		
T T		us- 6147203	11-14-2000	Pastan et al.		
		^{US-} 6074644	06-13-2000	Pastan et al.		
V		US- 5677425	10-14-1977	Bodmer et al.		
140		^{US-} 6482919	11-19-2002	Ledbetter et al.		
		US-				
		US-				
		US-		·		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
	Cite No.1	Foreign Patent Document Publication Date MM-DD-YYYY Country Code ³ "Number ⁴ "Xind Code ⁵ (if known)	1	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
				Or Relevant Figures Appear	ľ	
JA A		WO0044777	08-03-2000	IMCLONE SYSTEMS		
1		WO9221755	12-10-1992	GENENTECH INC		L
		EP0586002	03-09-1994	Macineira et al		
V		WO9509917	04-01-1995	COLOMA et al.		
LB		WO9405690	03-17-1994	Gross et al.		L
	1	.,				Г

Examiner	Date	2/4/2
Signature	Considered	<i>4/1//</i>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. The reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. The reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attention. Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PMO TRADEMA			are required to respond to a collection of Information unless it contains a valid OMB of Complete if Known			
Substitute for form 1449/F70 / HADEAM				Application Number	10/053,530	
INF	ORMATION	DIS	CLOSURE	Filing Date	January 17, 2002	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	LEDBETTER	
				Art Unit	1642	
(Use as many sheets as necessary)			ecessary)	Examiner Name	HELMS, LARRY R	
Sheet	2	of	2	Attorney Docket Number	49076-000004.utl2	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
2A		Munoz E. et The C(H)1 domain of IgG is not essential for C3 covalent binding: importance of the other constant domains as targets for C3. Int Immunol. 1998 Feb;10(2):97-106.		
i\$0		Martin S. et al., Efficient neutralization and disruption of rhinovirus by chimeric ICAM- 1/immunoglobulin molecules, J. Virol. 1993,67:3561-3568		
190		Stevenson G.T. et al., Mechanisms in removal of tumor by antibody. Cell Biophys. 1994;24-25:45-50.		
140		Anderson et al., Targeted anti-cancer therapy using rituximab, a chimeric anti-CD-20 antibody (IDEC-c2B8) in the treatment of non-hodgkin's B-cell lymphoma; Biochemical Society Transactions Colcester, Essex, GB, pg 705-708; 1997		
		·		
		·		
			,,	
Examiner Signature	-	Date Considered 2/4/05		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.